KDNY
Price:
$40.39
Market Cap:
$2.71B
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headq...[Read more]
Industry
Biotechnology
IPO Date
2020-10-06
Stock Exchange
NASDAQ
Ticker
KDNY
According to Chinook Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.63B. This represents a change of 46.26% compared to the average of 1.80B of the last 4 quarters.
The mean historical Enterprise Value of Chinook Therapeutics, Inc. over the last ten years is 1.72T. The current 2.63B Enterprise Value has changed -84.72% with respect to the historical average. Over the past ten years (40 quarters), KDNY's Enterprise Value was at its highest in in the June 2015 quarter at 7.98T. The Enterprise Value was at its lowest in in the December 2017 quarter at -157614000.00.
Average
1.72T
Median
520.90B
Minimum
62.85M
Maximum
6.29T
Discovering the peaks and valleys of Chinook Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 864.41%
Maximum Annual Enterprise Value = 6.29T
Minimum Annual Increase = -99.98%
Minimum Annual Enterprise Value = 62.85M
Year | Enterprise Value | Change |
---|---|---|
2022 | 1.61B | 165.71% |
2021 | 606.12M | 864.41% |
2020 | 62.85M | -73.77% |
2019 | 239.62M | -99.98% |
2018 | 1.04T | -61.95% |
2017 | 2.73T | -26.44% |
2016 | 3.72T | -40.92% |
The current Enterprise Value of Chinook Therapeutics, Inc. (KDNY) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
759.82M
5-year avg
208.54B
10-year avg
1.72T
Chinook Therapeutics, Inc.’s Enterprise Value is greater than DICE Therapeutics, Inc. (1.82B), greater than Pliant Therapeutics, Inc. (875.14M), less than Crinetics Pharmaceuticals, Inc. (5.03B), less than Ascendis Pharma A/S (7.61B), greater than Ventyx Biosciences, Inc. (133.12M), less than Nuvalent, Inc. (6.33B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Travere Therapeutics, Inc. (2.05B), greater than Structure Therapeutics Inc. (1.75B), less than Avidity Biosciences, Inc. (4.16B), less than Revolution Medicines, Inc. (8.00B), greater than Day One Biopharmaceuticals, Inc. (971.52M), less than SpringWorks Therapeutics, Inc. (3.07B), less than Arcellx, Inc. (4.55B), less than Vaxcyte, Inc. (10.57B), greater than Viridian Therapeutics, Inc. (1.40B), greater than KalVista Pharmaceuticals, Inc. (435.25M), greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than Kura Oncology, Inc. (817.88M),
Company | Enterprise Value | Market cap |
---|---|---|
1.82B | $2.27B | |
875.14M | $894.55M | |
5.03B | $5.30B | |
7.61B | $7.83B | |
133.12M | $183.85M | |
6.33B | $6.69B | |
8.24B | $8.19B | |
2.05B | $1.69B | |
1.75B | $1.92B | |
4.16B | $4.53B | |
8.00B | $8.12B | |
971.52M | $1.39B | |
3.07B | $3.15B | |
4.55B | $4.64B | |
10.57B | $11.60B | |
1.40B | $1.58B | |
435.25M | $460.85M | |
138.26M | $181.50M | |
817.88M | $850.73M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Chinook Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Chinook Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Chinook Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Chinook Therapeutics, Inc. (KDNY)?
What is the 3-year average Enterprise Value for Chinook Therapeutics, Inc. (KDNY)?
What is the 5-year average Enterprise Value for Chinook Therapeutics, Inc. (KDNY)?
How does the current Enterprise Value for Chinook Therapeutics, Inc. (KDNY) compare to its historical average?